Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma.

Intracellular drug measurements to predict toxicity in high-dose methotrexate therapy in leukaemia and central nervous system lymphoma: a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24644

Enrollment

Registered

2015-12-29

Start date

2016-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

leukaemia and central nervous system lymphoma acute leukemie en centraal zenuwstelsel lymfoom

Interventions

bloodsampling

Eligibility

Inclusion criteria

Inclusion criteria: - All adult patients treated in the Erasmus MC with HD-MTX for a CNS lymphoma or ALL - Written informed consent

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
To investigate the pharmacokinetics and determinants of MTX-PG accumulation in plasma, lymphocytes and erythrocytes in adult CNS lymphoma and leukemia patients treated with HD-MTX	—

Secondary

Measure	Time frame
To investigate whether intracellular MTX levels are related to toxicity in adult HD-MTX therapy	—

Contacts

Public ContactS. Heil

Erasmus MC, department of Clinical chemistry, Na-420

email: s.heil@erasmusmc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)